tuneTypical Dose
1000 mg/day, usually as MPFF
Flavonoid
Diosmin
Diosmin
Evidence TierCWADA NOT PROHIBITED
watchEffect Window
Symptom relief usually emerges over weeks rather than days.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
Diosmin has its clearest human evidence in chronic venous disease symptom relief, especially when used as micronized purified flavonoid fraction, with weaker supportive evidence for hemorrhoid symptoms.
Diosmin is better understood as a venoactive flavonoid than as a generic circulation supplement. The strongest human evidence is for chronic venous disease, particularly when diosmin is used in MPFF formulations, where symptom improvement for pain, heaviness, swelling, cramps, and discomfort is reasonably well supported. There is also supportive but lower-confidence evidence for hemorrhoid symptoms. The key limitation is that much of the stronger literature is tied to MPFF rather than to generic diosmin products, and some of the recent evidence is commercially exposed.
Diosmin is usually framed as a venoactive flavonoid that may improve venous tone, capillary permeability, and microcirculatory inflammation. The useful clinical evidence aligns with venous symptom relief rather than with broad systemic vascular claims.
Article
Diosmin
Diosmin is one of the more clinically grounded circulation-oriented supplements, but only when it is framed correctly.
The strongest use case is chronic venous disease, especially leg heaviness, pain, swelling, and related venous symptoms. That evidence mostly comes from micronized purified flavonoid fraction, not from a generic “bioflavonoid” concept.
What the evidence supports
A 2025 systematic review and meta-analysis found consistent symptom improvement with MPFF across chronic venous disease stages. Pain, heaviness, discomfort, cramps, swelling sensation, and burning all improved, with high overall patient satisfaction, although heterogeneity and risk of bias were often substantial.1
Diosmin-containing flavonoid preparations also have supportive hemorrhoid data. A 2006 meta-analysis found reductions in persisting symptoms, bleeding, pain, itching, and recurrence, but it also emphasized methodological limitations, heterogeneity, and possible publication bias.2
Practical framing
The strongest use cases are:
- chronic venous disease symptom relief
- supportive hemorrhoid symptom management
The weak use cases are:
- generic circulation support
- assuming all diosmin products are interchangeable with MPFF
Dosing
The best current venous-disease evidence is concentrated around MPFF 1000 mg daily for at least 1 month. That is the clearest evidence-aligned protocol.
Safety
Diosmin appears generally well tolerated, with mild GI upset or headache as the most practical adverse effects. It should still be treated like a symptom-management tool, not a replacement for compression therapy, vascular evaluation, or procedural care when those are indicated.
Bottom line
Diosmin is one of the more credible venous-symptom supplements, especially as MPFF. It has a real place in symptom relief for chronic venous disease and possibly hemorrhoids, but the confidence should stay tied to those specific indications and formulations.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- Improvement in chronic venous disease symptoms
Secondary Outcomes
- Supportive improvement in hemorrhoid symptoms
- Evidence strongest for MPFF rather than generic diosmin
Safety
Contraindications and Interactions
Contraindications
- Unexplained unilateral leg swelling or acute thrombotic symptoms
Side effects
- Mild GI upset
- Headache
Interactions
No entries provided
Avoid if
- You are using it instead of vascular evaluation or compression-based care when indicated
- You cannot verify the formulation quality
Evidence
Study-level References
di-SRC-001Systematic review and meta-analysis
Sourceopen_in_newNicolaides A, Lobastov K, Mansilha A, et al. Effectiveness of micronized purified flavonoid fraction on venous symptoms and signs in patients at all stages of chronic venous disease: a systematic review and meta-analysis. Part I: symptoms. Int Angiol. 2025;44(6):445-468. doi:10.23736/S0392-9590.25.05462-8. PMID:41324419.
Population: Patients with chronic venous disease across all CEAP stages from C0s to C6.
Dose protocol: MPFF 1000 mg daily for at least 1 month
Key findings: Improved pain, heaviness, discomfort, cramps, and swelling across chronic venous disease stages.
Notes: Best current evidence anchor for diosmin as MPFF.
Paper content
This is the best current anchor for diosmin, or more precisely MPFF, in chronic venous disease. It supports consistent symptom improvement for pain, heaviness, cramps, discomfort, and swelling, but heterogeneity was often high and many studies had high risk of bias. The evidence is still good enough to justify a real chronic-venous-disease record, especially when the formulation is clearly MPFF rather than generic diosmin.
di-SRC-002Systematic review and meta-analysis
Sourceopen_in_newAlonso-Coello P, Zhou Q, Martinez-Zapata MJ, et al. Meta-analysis of flavonoids for the treatment of haemorrhoids. Br J Surg. 2006;93(8):909-920. doi:10.1002/bjs.5378. PMID:16736537.
Population: Adults with symptomatic hemorrhoids across randomized controlled trials of flavonoid therapy.
Dose protocol: Various flavonoid protocols, often diosmin-containing
Key findings: Reduced persisting hemorrhoid symptoms, bleeding, and pain.
Notes: Useful supportive hemorrhoid review, but lower confidence.
Paper content
This meta-analysis suggests that flavonoid therapy, often including diosmin-containing formulations, can reduce symptomatic hemorrhoid persistence, bleeding, pain, and recurrence. The review also highlighted methodological limitations, heterogeneity, and potential publication bias, so hemorrhoid claims should stay supportive and low confidence rather than definitive.
di-SRC-003Systematic review and meta-analysis of randomized double-blind placebo-controlled trials.
Sourceopen_in_newKakkos SK, Nicolaides AN. Efficacy of micronized purified flavonoid fraction (Daflon) on improving individual symptoms, signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebo-controlled trials. Int Angiol. 2018;37(2):143-154. doi:10.23736/S0392-9590.18.03975-5. PMID:29385792.
Population: Patients with chronic venous disease across 7 RCTs.
Dose protocol: MPFF (Daflon) versus placebo across 7 RCTs
Key findings: MPFF significantly improved nine individual venous symptoms including pain (RR 0.53), heaviness (RR 0.35), and skin changes (RR 0.18).
Notes: Strongest pooled placebo-controlled evidence for MPFF efficacy in chronic venous disease.
Paper content
This systematic review and meta-analysis pooled data from 7 randomized double-blind placebo-controlled trials (1,692 patients) evaluating MPFF for chronic venous disease symptoms. MPFF significantly improved nine individual leg symptoms compared to placebo, including pain (RR 0.53), heaviness (RR 0.35), and skin changes (RR 0.18). Quality of life measures also improved. The analysis provides the strongest pooled evidence that MPFF is effective for symptom relief across the full spectrum of chronic venous disease. Limitations include moderate heterogeneity and commercial sponsorship of some included trials.